Daclizumab biosimilar (Shanghai CP Guojian)

达克珠单抗单抗生物类似药（三生国健）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDaclizumab biosimilar (Shanghai CP Guojian)
Drug Alias Name重组抗CD25人源化单克隆抗体注射液（三生国健）Daclizumab (Shanghai CP Guojian)重组抗CD25人源化单抗（三生国健）Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection (anti-CD25 rhMAb)Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsRejection of renal transplantation
Global Approved IndicationsRejection of renal transplantation
Approved Indications in ChinaRejection of renal transplantation
Original Approved Country/TerritoryMainland China
Original Approved Date2011/01/12
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsN/A

Other Information

ATC CodeL04AC01
Related LinksN/A